Biotechnology News and Research

RSS

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification.

21 Jun 2011

Rheonix, Mayo Clinic partner for genotyping test to assist warfarin sensitivity

Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings.

21 Jun 2011

Sentrx, TransPerfect collaborate to offer Trial Interactive Portal Technology

TransPerfect and Sentrx have announced a collaboration involving TransPerfect's Trial Interactive Portal Technology, which will streamline end-to-end global drug safety capabilities in both clinical and post-marketing event management.

21 Jun 2011

Mayo Clinic announces collaboration on genotyping test for Warfarin sensitivity

Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The genotyping test will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. Additionally, the test will be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories, to clients throughout the world.

20 Jun 2011

bioMD (BOD) announces new MD, new Chairman and Board

bioMD Limited (ASX:BOD), a company with assets in regenerative tissue engineering technologies today announced the appointment of a new Chairman, a new MD and other changes to its Board. This follows shareholder approval for the acquisition of Allied Medical Ltd., a company that specialises in the sales, distribution and commercialisation of medical technologies.

20 Jun 2011

EPA, ACS present 2011 Presidential Green Chemistry Challenge Award to BioAmber

BioAmber, Inc. has been awarded a 2011 Presidential Green Chemistry Challenge Award, presented by the Environmental Protection Agency (EPA) and the American Chemical Society (ACS). The Award promotes technology that provides substantial environmental benefits using green chemistry. BioAmber's platform was recognized as the leading technology in the field of succinic acid.

20 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that various studies on ZEVALIN for Injection were presented at the 11th International Conference on Malignant Lymphoma (ICML), held June 15-18, 2011, in Lugano, Switzerland.

20 Jun 2011

Perceptive's Clinical Trial Management System now available as SaaS application

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that its Clinical Trial Management System is available as an on-demand, software-as-a-service (SaaS) application.

From Parexel 20 Jun 2011

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

20 Jun 2011

Concert earns $4M milestone payment from GSK collaboration

Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone in its strategic alliance with GlaxoSmithKline for its HIV protease inhibitor development program, resulting in a $4 million milestone payment to Concert.

20 Jun 2011

Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany's healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by Enterohemorrhagic Escherichia coli in an unusually wide outbreak in Germany that began in May.

20 Jun 2011

Novel biomarker-development pipeline approach for human diseases

Researchers at Fred Hutchinson Cancer Research Center have demonstrated in mice that the performance of a novel biomarker-development pipeline using targeted mass spectrometry is robust enough to support the use of an analogous approach in humans.

20 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

European Patent Office issues notice of allowance to Kuros' synthetic biomaterials

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today the allowance of European Patent Application 00910049 by the European Patent Office.

20 Jun 2011

Genomic study identifies MCU that regulates calcium transport into mitochondria

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Massachusetts General Hospital (MGH), the Broad Institute, and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), today announced new findings published in Nature.

20 Jun 2011

Australian Government announces new tax credit system for R&D activities

Providing a valuable incentive for U.S. investment in Australia, the Australian Government announced an agreement under which the Parliament will enact a AU$1.8 billion R&D tax credit that will deliver funding to innovative firms in industries including advanced manufacturing, information and communications technologies, and biotechnology.

18 Jun 2011

CoreLab Partners' new technological solutions to be showcased at DIA 2011

CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm, Inc and Medifacts International, will showcase several new technological solutions to coincide with the upcoming DIA meeting in Chicago, Illinois to be held from June 20 - 23, 2011.

17 Jun 2011

Enterologics to acquire BioBalance from NYHC

Enterologics, Inc. announced today that it is acquiring all the shares of The BioBalance Corporation and its subsidiary BioBalance LLC from New York Health Care, Inc.

17 Jun 2011